Author

V. Hammer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

N. Casadei· 2 shared O. Riess· 2 shared R. Bajaj· 2 shared S. Ossowski· 2 shared Y. Singh· 2 shared A. Schulze-Selting· 1 shared C. Ruschil· 1 shared D. M. Altmann· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

N. Casadei

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Comparative multi-OMICS single-cell atlas of five COVID-19 (rAdVV and mRNA) vaccines describe unique and distinct mechanisms of action

Y. Singh, A. Schulze-Selting, G. Gabernet, U. Ray, R. Bajaj, M. Ali, M. Loitz, V. Hammer, E. Buena-Atienza, C. Ruschil, J. Huebner, M. Kowarik, M. salker, N. Casadei, S. Nahnsen, , O. Riess

This study compares the mechanisms of action of five COVID-19 vaccines using multi-omics single-cell data, revealing distinct immune responses and cell-type-specific effects.

bioRxiv · Sep 12, 2022 · PreprintImmunology

Immune dynamics at single cell protein level after delta/omicron infection in COVID-19 vaccinated convalescent individuals

R. Bajaj, Z. Yang, V. Hammer, S. Poeschel, K. Beiber, M. S. Salker, N. Casadei, S. Ossowski, O. Riess, Y. Singh

This study examines immune dynamics at the protein level in vaccinated individuals infected with delta or omicron variants, finding reduced NK cells and increased T and B cells, and that booster doses reduce infection severity.

bioRxiv · Sep 5, 2022 · PreprintImmunology